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education of staff regarding the policy and procedure and the 
newly revised missed appointment log has been instituted. With 
the revision of the missed appointment log, the nurse can track 
the type of appointment missed, the physician, reasons for the 
missed appointments, and impending follow up. As for new 
patients or consults, a change was implemented requiring the 
scheduler to contact the patient confirming the appointment date 
and time. This is a project hat will and has led ns to look at ways 
to improve clinic flow to assure that patients are receiving the best 
quality of care before and after t ansplant. 
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WHEN DYSPNEA BECOMES AN ONCOLOGIC EMERGENCY FOR 
BLOOD AND MARROW TRANSPLANTATION (BMT) PATIENTS: DIF- 
FUSE ALVEOLAR HEMORRHAGE 
Hi~cls, L.; Brandert, M.; Neuman~, J. University of Texas MD 
Amterson Cmzcer CeJ~te~, HoHsto~, TX. 
Diffuse alveolar hemorrhage (DAH) in any patient can Iead to a 
life-threatening situation, but in general the risk of occurrence is
low with reported incidents varied from 2-20%. Prompt reatment 
is essential. When untreated mortality hasbeen reported in excess 
of 75%. In the BMT patient the risk factors are increased for sev- 
eral reasons aside from low platelets during the period of pancy- 
topenia. Other risk factors include: chemotherapy, total body irra 
diation (TBI), infection, and old age. Because of these risk factors, 
the clinical nurse caring for the BMT patient during the period of 
engraftment is responsible for being hyper-vigilant and acting 
immediately upon subtle respiratory changes. The signs and 
symptoms of DAH include: dyspnea; hemoptysis; hypoxia demon- 
strated by decrease in 02 saturations; change in respiratory status- 
cough, tachypnea, use of accessory muscles, decrease in breath 
sounds; anxiety; confiision; restlessness; and heart palpitations. At 
our comprehensive cancer center where over 500 BMT patients 
are treated and cared for each year, the unit-based clinical practice 
council has developed a DAH standard of care that identifies prac- 
tice guidelines. These include general information about DAH 
and principles of treatment; our policy containing uidelines and 
responsibilities of the nurse to inform the medical team; and nurs 
ing interventions. On our unit these interventions may include: 
administration of Solu-Medrol, Lasix, DDAVP, Amicar, and a 
cough suppressant; initiation of O2 to keep saturations above 
95%; and infusing platelets. Additional diagnostic assessments 
may include ABGs, portable chest x-ray, and bronchoscopy. Pro- 
tocols involving the use of activated Factor VII for DAH are also 
being examined to improve hemostasis. Recognition of acute 
bleeding, including DAH, is a competency that is tested yearly on 
our unit. DAH case reviews are discussed at stafffclinical practice 
meetings. A case review, including immediate nursing interven- 
tions, and outcomes data of DAH at our center will be presented. 
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THROMBOTIC THROMBOCYTOPENIA PURPURA AND HEMOLYTIC 
UREMIC SYNDROME IN BONE MARROW TRANSPLANT 
Shelb~lrl~e, N.F. Nurshlg Department, NatioJml h~stitlltes of H ahh, 
Silver Sp'rilzg, kiD. 
Thrombotic thrombocytopenia purpura (TTP) and hemolytic 
uremic syndrome (HUS) are multisystem, microvascular, platelet 
clumping disorders, associated with cancer, chemotherapy, 
immunosuppressive drugs, and bone marrow transplant (BMT). 
TTP and HUS, although rare, have a high mortality rate even 
with early recognition and intervention. Endothelial cell damage, 
secondary to irradiation, chemotherapy, and immunosuppressive 
drugs, initiates a cellular cascade that places BMT patients at risk 
for developing TTP  and HUS. The clinical manifestations of
these syndromes include hemolytic anemia, thrombocytopenia, 
renal failure, fever, and neurological changes. In BMT patients, 
making an early diagnosis of these syndromes may be difficult 
with thrombocytopenia and anemia lready present. The standard 
treatment for BMT related T I 'P  and HUS are plasma exchange 
and change of innnunosuppressive agents, as cyclosporine and 
tacrolimns (FKS06) have been implicated in causing these syn- 
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dromes. Von YVillebrand factor (vWF) is a normally occurring 
factor in the blood that assists in platelet aggregation, but in TFP 
and HUS, there is an excess number that are abnormal in size. 
Plasma exchange is used to remove the abnormal vWF and 
replace normal vYVF. In addition, supportive care includes trans- 
fusions for anemia, and hemodialysis for renal failure. The admin- 
istration of platelets for thrombocytopenia can exacerbate these 
syndromes. TTP and HUS can be difficult o identify early before 
multi-system and systemic involvement. The BMT nurses role is 
to understand these complications and ensure appropriate moni 
toting and early intervention to include assessment for: signs of 
anemia and thrombocytopenia, need for transfusions, changes in 
neurological status, weight and input/output monitoring as an 
indicator of renal function, and patient/family education. In con- 
chision, the bone marrow transplant population is at risk for TTP 
and HUS. The key to a successful outcome includes assessment 
sldlls, laboratory monitoring, and management of the multi-sys- 
tem involvement. 
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EARLY CMV REACTIVATION IS ASSOCIATED WITH GANCICLOVIR 
PROPHILAXIS ADMINISTRATED BEFORE TRANSPLANTATION 
PactJanov, E.D.; Balashov, D.N.; Skorobogwtova, E.V.; Dyshlevaia, 
Z.3/I.; S,bipitsina, LP.; Skvo~-tsova, Y. Id; ResJfick, LB.; NIaschan, A.A.; 
RTmfim~tsev, A.G. Researct: hzsftute of Pedarric Hematology, Moscow, 
Moscow, Rassirm Fedevatio**. 
We performed an analysis of incidence of CMV reactivation and 
morbidity in 71 children undergoing allogeneic HSCT during 8 
years (1994 2002). Thirty eight patients uffered from hematologi- 
cal malignancies (incl. AML, ALL, CML, MDS, lyanphoma) nd 33 
from non-malignant diseases (incl. SAA, FA, hemophagocytic syn- 
dromes, SCID, ALPS with secondary AML). Patients and methods. 
28 consecutive allo-patients in i994 - 1998 received the preventive 
ganciclovir, from day - 8 to day - 2, in order to obtain the prophylax- 
is of CMV reactivation i  post-transplant. Since 1999, 43 allo- 
patients did not received preventive ganciclovir before transplant. 
Both cohorts of patients were comparable. Results. Overall incidence 
of CMV infection, confirmed by PCR detection of virus, was 19/7 I 
transplant recipients (26, 8 %). We observed that 13/28 (46, 4 %) 
patients of ganciclovir group had a CMV reactivation, and 3 of 13 
had a confirmed CMV disease (pnemnonia 2 and colitis 1). In con- 
trast, only 6/43 (14 %) patients without ganciclovir before transplant 
demonstrated a CMV reactivation with no evidence of CMV disease. 
Conclusion. Our data suggests that prevention of CNIV reactivation 
and morbidity with ganciclovir administrated before transplant does 
not reduce the incidence of CMV infection, and furthermore the 
incidence of CMV vircmJa is parado~cally higher in patients receiv- 
ing ganciclovir prophylaxis. It may be related with retardation of 
early anti-CMV T-ceil response resulted from suppression ofhypo- 
thetically existing latent infection. We conclude that preventive gan- 
ciclovir before HSCT is not expedient. On the other hand, PCR 
monitoring of CMV infection and pre-emptive treatment ofviremia 
show their efficacy and seem to be necessary inHSCT setting. 
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DEVELOPMENT AND UTILIZATION OF A UNIFIED STRATEGIC BUSI- 
NESS PLAN FOR MARKETING BLOOD AND MARROW TRANSPLANT 
OUTPATIENT CLINIC SERVICES THE GOAL IS TO INCREASE AWARE- 
NESS OF OUTPATIENT TRANSPLANTS AND INCREASE REFERRALS 
Mebane, J.J.; Agm~a, E.D.; Be~D,THa~7 , R.B.; Fay, .7. FP:; Pmeiro, L.; 
Ua~zce, E.A.; ~q~ilso~z, A/I.C. Baylor Sammolls CmTcer Center m~d Texas 
011colo©,, P.A., Dallas, TA2 
Blood and Marrow Transplant Services, PLLC is a subsidiary of 
Texas Oncology, P.A. The outpatient clinic recently doubled in 
size to 14, 000 square feet in capacity with 6 private rooms, 16 
infusion chairs and I5 exam rooms. Charged with the goal of 
increasing awareness of outpatient transplants and referrals, clinic 
administration developed a strategic plan through surveying 
physicians, patients and clinic personnel. After compiling all the 
data received in the surveys, we developed a strategic plan through 
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the following segmentation: Market Analysis Demand Customer 
Identification Product Life Cycle Market Depth Trends The 
Industry Size Market Structure Overview of Competition Indus- 
try Life Cycle Industry Trends The Competition Main Com- 
petitors Basis of Competition Competitive Advantage Marketing 
Plan Transplant Projections Market Segment Reaching Cus- 
tomers Awareness Sales Strateg T The main components of the 
plan include clinic operations improvement, managed care and 
insurance contracting initiatives, and marketing and referral pro- 
grain development. The plan includes how we communicate inter- 
nally and externally. This plan also includes the development of
our outreach program for referring physicians. The outreach pro- 
gram gives easy access to our BMT physicians for consultation 
and to gain answers to question posed by referring physicians. 
Another goal of this program is to show the cost-effectiveness of 
the outpatient program to the insurance/payer community. A fiir- 
ther goal is meeting with all managed care and insurance compa- 
nies to provide ongoing education pertaining to outpatient blood 
and marrow transplant services. Only through development of 
such a comprehensive system, can outpatient transplants be real- 
ized in an era of diminishing health resources and changing tech- 
nologies. 
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